1.
Open Forum Infect Dis
; 9(11): ofac565, 2022 Nov.
Article
in English
| MEDLINE | ID: covidwho-2107557
ABSTRACT
There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).